136 related articles for article (PubMed ID: 36808757)
1. PX-12 synergistically enhances the therapeutic efficacy of vorinostat under hypoxic tumor microenvironment in oral squamous cell carcinoma in vitro.
Akhlaq R; Khan T; Ahmed T; Musharraf SG; Ali A
Drug Dev Res; 2023 May; 84(3):556-560. PubMed ID: 36808757
[TBL] [Abstract][Full Text] [Related]
2. The histone deacetylase inhibitor, Vorinostat, represses hypoxia inducible factor 1 alpha expression through translational inhibition.
Hutt DM; Roth DM; Vignaud H; Cullin C; Bouchecareilh M
PLoS One; 2014; 9(8):e106224. PubMed ID: 25166596
[TBL] [Abstract][Full Text] [Related]
3. Overcoming chemotherapy resistance using pH-sensitive hollow MnO
Zhou ZH; Liang SY; Zhao TC; Chen XZ; Cao XK; Qi M; Huang YY; Ju WT; Yang M; Zhu DW; Pang YC; Zhong LP
J Nanobiotechnology; 2021 May; 19(1):157. PubMed ID: 34039370
[TBL] [Abstract][Full Text] [Related]
4. The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endothelial growth factor formation.
Welsh SJ; Williams RR; Birmingham A; Newman DJ; Kirkpatrick DL; Powis G
Mol Cancer Ther; 2003 Mar; 2(3):235-43. PubMed ID: 12657718
[TBL] [Abstract][Full Text] [Related]
5. PX-478, an inhibitor of hypoxia-inducible factor-1alpha, enhances radiosensitivity of prostate carcinoma cells.
Palayoor ST; Mitchell JB; Cerna D; Degraff W; John-Aryankalayil M; Coleman CN
Int J Cancer; 2008 Nov; 123(10):2430-7. PubMed ID: 18729192
[TBL] [Abstract][Full Text] [Related]
6. Dysregulation of hypoxia inducible factor-1alpha in head and neck squamous cell carcinoma cell lines correlates with invasive potential.
Cohen NA; Lai SY; Ziober AF; Ziober BL
Laryngoscope; 2004 Mar; 114(3):418-23. PubMed ID: 15091212
[TBL] [Abstract][Full Text] [Related]
7. Anti-inflammatory properties of histone deacetylase inhibitors: a mechanistic study.
Chong W; Li Y; Liu B; Liu Z; Zhao T; Wonsey DR; Chen C; Velmahos GC; deMoya MA; King DR; Kung AL; Alam HB
J Trauma Acute Care Surg; 2012 Feb; 72(2):347-53; discussion 353-4. PubMed ID: 22327976
[TBL] [Abstract][Full Text] [Related]
8. Ru(II)-modified TiO
Zhou JY; Wang WJ; Zhang CY; Ling YY; Hong XJ; Su Q; Li WG; Mao ZW; Cheng B; Tan CP; Wu T
Biomaterials; 2022 Oct; 289():121757. PubMed ID: 36058028
[TBL] [Abstract][Full Text] [Related]
9. Changes in the Expression of TBP-2 in Response to Histone Deacetylase Inhibitor Treatment in Human Endometrial Cells.
Kim HI; Seo SK; Chon SJ; Kim GH; Lee I; Yun BH
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33572677
[TBL] [Abstract][Full Text] [Related]
10. Se-methylselenocysteine sensitizes hypoxic tumor cells to irinotecan by targeting hypoxia-inducible factor 1alpha.
Chintala S; Tóth K; Cao S; Durrani FA; Vaughan MM; Jensen RL; Rustum YM
Cancer Chemother Pharmacol; 2010 Oct; 66(5):899-911. PubMed ID: 20066420
[TBL] [Abstract][Full Text] [Related]
11. HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT.
Bruzzese F; Leone A; Rocco M; Carbone C; Piro G; Caraglia M; Di Gennaro E; Budillon A
J Cell Physiol; 2011 Sep; 226(9):2378-90. PubMed ID: 21660961
[TBL] [Abstract][Full Text] [Related]
12. Differentiated embryo chondrocyte 1, induced by hypoxia-inducible factor 1α, promotes cell migration in oral squamous cell carcinoma cell lines.
Yang L; Zeng L; Wang Z; Hu X; Xiong H; Zhang T; Chen W; Xia K; Su T
Oral Surg Oral Med Oral Pathol Oral Radiol; 2022 Feb; 133(2):199-206. PubMed ID: 34758939
[TBL] [Abstract][Full Text] [Related]
13. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.
Ahrens TD; Timme S; Hoeppner J; Ostendorp J; Hembach S; Follo M; Hopt UT; Werner M; Busch H; Boerries M; Lassmann S
Epigenetics; 2015; 10(5):431-45. PubMed ID: 25923331
[TBL] [Abstract][Full Text] [Related]
14. Hypoxia-independent gene expression signature associated with radiosensitisation of prostate cancer cell lines by histone deacetylase inhibition.
Jonsson M; Ragnum HB; Julin CH; Yeramian A; Clancy T; Frikstad KM; Seierstad T; Stokke T; Matias-Guiu X; Ree AH; Flatmark K; Lyng H
Br J Cancer; 2016 Oct; 115(8):929-939. PubMed ID: 27599042
[TBL] [Abstract][Full Text] [Related]
15. Replication Stress Leading to Apoptosis within the S-phase Contributes to Synergism between Vorinostat and AZD1775 in HNSCC Harboring High-Risk
Tanaka N; Patel AA; Tang L; Silver NL; Lindemann A; Takahashi H; Jaksik R; Rao X; Kalu NN; Chen TC; Wang J; Frederick MJ; Johnson F; Gleber-Netto FO; Fu S; Kimmel M; Wang J; Hittelman WN; Pickering CR; Myers JN; Osman AA
Clin Cancer Res; 2017 Nov; 23(21):6541-6554. PubMed ID: 28790110
[No Abstract] [Full Text] [Related]
16. Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors.
Zang Y; Kirk CJ; Johnson DE
Cancer Biol Ther; 2014 Sep; 15(9):1142-52. PubMed ID: 24915039
[TBL] [Abstract][Full Text] [Related]
17. Antitumor agent PX-12 inhibits HIF-1α protein levels through an Nrf2/PMF-1-mediated increase in spermidine/spermine acetyl transferase.
Kim YH; Coon A; Baker AF; Powis G
Cancer Chemother Pharmacol; 2011 Aug; 68(2):405-13. PubMed ID: 21069338
[TBL] [Abstract][Full Text] [Related]
18. Alteration of cancer stem cell-like phenotype by histone deacetylase inhibitors in squamous cell carcinoma of the head and neck.
Chikamatsu K; Ishii H; Murata T; Sakakura K; Shino M; Toyoda M; Takahashi K; Masuyama K
Cancer Sci; 2013 Nov; 104(11):1468-75. PubMed ID: 23992541
[TBL] [Abstract][Full Text] [Related]
19. The involvement of hypoxia-inducible factor-1alpha in the susceptibility to gamma-rays and chemotherapeutic drugs of oral squamous cell carcinoma cells.
Sasabe E; Zhou X; Li D; Oku N; Yamamoto T; Osaki T
Int J Cancer; 2007 Jan; 120(2):268-77. PubMed ID: 17066447
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-18a regulates the metastatic properties of oral squamous cell carcinoma cells via HIF-1α expression.
Kim S; Park S; Oh JH; Lee SS; Lee Y; Choi J
BMC Oral Health; 2022 Sep; 22(1):378. PubMed ID: 36064348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
